new Chemotherapy ‍Regimen‍ Improves Fertility in Young Hodgkin Lymphoma Patients

Young adults diagnosed with advanced Hodgkin lymphoma now have a considerably improved​ chance of preserving their fertility thanks to a new chemotherapy regimen, according to a groundbreaking⁣ international study.The research, led by the German ⁢Hodgkin Study Group (GHSG) at University Hospital cologne, demonstrates that the​ BrECADD regimen offers comparable recovery rates to the previous standard, eBEACOPP, while substantially improving hormonal⁣ recovery and ⁢increasing the ‍likelihood of ⁢future parenthood.

BrECADD vs. eBEACOPP: A‍ comparative Analysis

Hodgkin lymphoma, a cancer affecting⁤ the lymphatic system, ofen requires aggressive chemotherapy. While effective in treating the disease, conventional treatments can have detrimental effects on fertility, particularly in young patients. The HD21 trial directly compared two chemotherapy approaches: the established eBEACOPP and the newer brecadd regimen.The study, a randomized phase III clinical trial involving over 1,500 participants under⁣ 60⁢ years old across 233 centers in nine countries, focused on assessing the ‌recovery of hormone levels and documenting pregnancies and births following treatment completion. Results revealed a marked difference in hormonal recovery rates.

Three years post-treatment,95% of women and 86% of men in the BrECADD group exhibited normal hormone levels,compared to just 73% and 40% respectively in the eBEACOPP ‍group. This translates⁣ to a significantly higher probability of biological paternity for men and a greater chance of successful pregnancies ‌for women. ‍The findings where published in The Lancet Oncology under the title “Fertility ⁣in patients with advanced-stage classic ⁣Hodgkin lymphoma treated with BrECADD versus ‍eBEACOPP: a secondary analysis of the multicentre, randomised, ⁤parallel, open-label, phase 3 HD21 Trial.”

Impact on Fertility and Family planning

The implications of​ this research are profound for young Hodgkin lymphoma patients considering future family planning. ​The BrECADD ⁣regimen not only maintains comparable cure rates but actively‌ supports reproductive health.

“BrECADD​ gives young adults ⁤with Hodgkin’s lymphoma a better⁤ chance of starting a family later in life -‍ with an equally good or even slightly better cure rate,” explains Dr. Justin Ferdinandus,​ Study physician in the GHSG and first author of the publication.

This advancement is particularly crucial given the increasing trend of individuals delaying parenthood until later in life. Preserving fertility during cancer treatment allows patients ​to make informed decisions about their future without compromising their health or family aspirations.

A New Standard of Care

The⁣ positive outcomes of the HD21 trial are already influencing clinical practice. Dr. Karolin Behringer, Study Physician at the GHSG and ⁢last author of the study, states, “The HD21 study ‍is fundamentally changing‍ practice. Our data⁤ clearly show that BrECADD is the preferred first-line treatment for patients who wish to ‍have children – at University Hospital Cologne and in the current Onkopedia guideline, this is already the new standard.”

The study examined hormone levels via blood serum levels of follicle-stimulating hormone, providing a quantifiable measure of ‍reproductive function recovery. The shift towards BrECADD represents a meaningful advancement⁤ in patient-centered cancer care, prioritizing both disease eradication and long-term quality of life.

Study Details and Funding

The HD21 trial was a⁢ multicentre, randomised, parallel, open-label, phase 3 clinical trial. The research was generously supported by Takeda Oncology.

Source:

Ferdinand, J., et al. (2025). Fertility in patients​ with advanced-stage classic Hodgkin lymphoma‍ treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial. The​ Lancet Oncology. https://doi.org/10.1016/S1470-2045(25)00262-100262-1)